Summary & Overview
HCPCS Q4156: Neox 100 or Clarix 100, per 100 cm²
HCPCS Level II code Q4156 denotes the use of a 100 cm² unit of Neox 100 or Clarix 100 as an add-on product billed in addition to a primary procedure. This designation is important for accurate billing of biologic and tissue-derived products used to support wound healing, grafting, or reconstruction in operative settings. Nationally, ensuring correct use of add-on codes like Q4156 affects reimbursement accuracy, billing transparency, and clinical documentation standards.
Key payers considered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find concise benchmarks and policy context for how add-on biologic products are billed and classified, common billing modifiers and their reporting contexts, and clinical scenarios where Q4156 is most frequently applied. The publication also outlines documentation elements typically required to support billing for adjunct biologic products and highlights payer coverage considerations and coding practice variations.
This summary is intended for national audiences including billing professionals, hospital coding teams, and clinical leaders seeking a clear reference on the classification and practical billing context of HCPCS Level II code Q4156.
Billing Code Overview
HCPCS Level II code Q4156 describes Neox 100 or clarix 100, per square centimeter and is designated as an add-on, billed separately in addition to a primary procedure. The code captures the application or use of a 100 cm² unit of these biologic or tissue-derived products when they are used as adjuncts to a primary surgical or wound management procedure.
Service type: Adjunct biologic/tissue product application
Typical site of service: Operative or procedural settings, including hospital operating rooms, ambulatory surgical centers, and other settings where surgical wound management or reconstructive procedures occur. Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with a chronic, non-healing dermal wound (for example, a diabetic foot ulcer or a large venous stasis ulcer) who has undergone debridement or other wound bed preparation and requires application of a biologic dermal matrix product such as Q4156 (Neox 100 or Clarix 100) per square centimeter as an add-on to the primary wound procedure. The clinical workflow begins with wound assessment in an outpatient wound clinic or inpatient surgical service. After documentation of indications, wound size, and prior conservative measures, the provider performs necessary wound bed preparation (sharp debridement, irrigation) and records the surface area in square centimeters. The biologic product Q4156 is applied to the prepared wound and secured per product instructions; the primary procedure code for the wound application or grafting is reported separately, and Q4156 is billed as an add-on per square centimeter. Post-application care includes dressing changes, infection surveillance, and follow-up visits in the wound clinic or surgical clinic. Typical sites of service include outpatient wound centers, hospital outpatient departments, and inpatient surgical units. Common patient scenarios include large, chronic ulcers, post-excisional soft tissue defects requiring biologic matrix support, and complex surgical wounds with compromised soft tissue coverage where a biologic scaffold is indicated.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|